Tag: In Vitro Cancer Diagnostics (IVD) Market Size

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Cancer In Vitro Diagnostics (IVD) Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The market for in vitro diagnostics (IVD) within the oncology sector has experienced substantial expansion, with projections indicating continued robust growth. Specifically, the market is anticipated to increase from $14.32 billion in 2025 to $15.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this growth during the historical period include the enhancement of diagnostic facilities within hospitals, an increase in testing focused on biomarkers, the greater utilization of PCR and immunoassay techniques, the proliferation of cancer screening initiatives, and advancements in laboratory automation.

The international market segment for in vitro diagnostics (IVD) within the oncology sector is poised for substantial expansion, projecting a valuation of $19.85 billion by the year 2030, propelled by a 6.7% compound annual growth rate (CAGR). This anticipated advancement stems from several key drivers, including a heightened need for customized cancer diagnostic solutions, escalating financial commitments towards genomic sequencing technologies, a broadening scope for point-of-care cancer diagnostic services, the increasing incorporation of cloud-based diagnostic systems, and a more pronounced emphasis on the principles of precision medicine. Furthermore, prominent developments anticipated within this timeframe encompass a greater embrace of molecular and genomic approaches to cancer testing, expanded utilization of companion diagnostics, more pervasive integration of artificial intelligence for data analysis, widening applications for liquid biopsy techniques, and an intensified concentration on strategies for the early identification of cancer.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp

Cancer In Vitro Diagnostics (IVD) Market Development Factors: Which Trends Are Supporting Demand?

The escalating prevalence of cancer is anticipated to be a primary catalyst for the expansion of the cancer in vitro diagnostics (IVD) market. Cancer, characterized by the unchecked proliferation and dissemination of aberrant cells within the body, possesses the capacity to infiltrate adjacent tissues and manifest as tumors. This heightened incidence is largely attributable to an aging global population, where increased lifespans and a decrease in mortality from infectious diseases contribute to a larger segment of individuals in higher-risk age groups for cancer development. Cancer IVD plays a crucial role in addressing the disease by facilitating its early and precise identification, tracking its progression, and aiding in its management through laboratory analyses of patient samples, which ultimately lead to prompt therapeutic interventions and enhanced patient prognoses. As an illustration, preliminary data shared in January 2023 by the American Cancer Society, a prominent US non-profit organization committed to cancer eradication, indicated projections of 1,958,310 new cancer diagnoses and 609,820 cancer-related fatalities within the United States for the year 2023. Consequently, the rising occurrence of cancer is directly stimulating the growth trajectory of the cancer in vitro diagnostics (IVD) sector.

Cancer In Vitro Diagnostics (IVD) Market Segmentation: How Is The Market Structured Across Key Categories?

The cancer in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Reagents And Kits, Instruments, Software And Services

2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Cytogenetics Or Liquid Biopsy Technologies, Molecular Diagnostics, Other Technology

3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer

4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Specialty Oncology Diagnostic Centers, Other End Users

Subsegments:

1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others

2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others

3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services

Cancer In Vitro Diagnostics (IVD) Market Transformation Trends: Which Innovations Are Driving Change?

Through advancements in cancer detection, key players within the cancer in vitro diagnostics sector are prioritizing novel screening methods, specifically targeting blood-based approaches for colorectal cancer (CRC) to facilitate accessible, non-invasive, and precise early identification of the disease; this blood-based screening involves the analysis of a patient’s blood for cancer-related molecular changes like circulating tumor DNA (ctDNA), thereby enabling the detection of colorectal cancer in individuals at average risk; a notable development occurred in July 2024 when Guardant Health, Inc., a prominent U.S. precision oncology firm, secured FDA approval for its Guardant Shield blood test, positioning it as a primary screening tool for colorectal cancer, which operates by examining blood for distinct ctDNA methylation signatures and other tumor markers, offering advantages such as a non-invasive sample collection process, superior analytical precision, and seamless integration into clinical practice for initial screening purposes, with its utility extending to the early detection of colorectal cancer in average-risk adults and yielding benefits like enhanced patient compliance, earlier diagnosis of cancerous conditions, a potential decrease in diagnoses at advanced stages, and qualification for Medicare coverage, thus expanding screening accessibility to a wider demographic.

Cancer In Vitro Diagnostics (IVD) Market Competitive Landscape And Leading Companies

Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics

Access The Complete Cancer In Vitro Diagnostics (IVD) Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

#Cancer In Vitro Diagnostics (IVD) Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Cancer In Vitro Diagnostics (IVD) Market Through 2030?

The cancer profiling market has seen significant growth in recent years. This market is projected to expand from $15 billion in 2025 to $16.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this historical growth include a rise in cancer incidence, the proliferation of molecular diagnostics laboratories, the early incorporation of genomic testing in oncology, an increase in research-driven cancer profiling activities, and the growing accessibility of diagnostic platforms.

The cancer profiling market is anticipated to experience significant expansion in the coming years. This market is projected to reach $25.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this growth over the forecast period include a rising demand for precision medicine methods, the broadening scope of companion diagnostics, the expanding application of liquid biopsy technologies, escalating investments in oncology diagnostics, and the increasing incorporation of profiling into standard clinical practices. Key trends during this period encompass the growing acceptance of NGS-based cancer profiling, an increase in the utilization of comprehensive genomic panels, the surging integration of AI in data analysis, the broadening of personalized oncology diagnostics, and a heightened emphasis on early molecular detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp

What Major Growth Factors Are Impacting The Cancer In Vitro Diagnostics (IVD) Market?

The cancer profiling market is anticipated to expand due to the rising occurrence of cancer. Cancer incidence denotes the count of new cancer cases identified within a specific population during a given timeframe. This increased incidence of cancer is attributed to factors such as urbanization, an expanding aging population, evolving lifestyles, and both environmental and genetic influences. Cancer profiling helps in pinpointing specific molecular or genetic alterations in a tumor, including gene mutations or other modifications in tumor DNA, which is beneficial throughout the cancer treatment process. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, translating to over 450 cases each day, with males accounting for approximately 55% of these diagnoses. Consequently, the growing incidence of cancer is a key factor propelling the growth of the cancer profiling market.

What Key Segment Areas Are Included In The Cancer In Vitro Diagnostics (IVD) Market Assessment?

The cancer in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Reagents And Kits, Instruments, Software And Services

2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Cytogenetics Or Liquid Biopsy Technologies, Molecular Diagnostics, Other Technology

3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer

4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Specialty Oncology Diagnostic Centers, Other End Users

Subsegments:

1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others

2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others

3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services

Which Trends Are Guiding The Development Of The Cancer In Vitro Diagnostics (IVD) Market?

Leading companies within the cancer profiling market are concentrating on technological advancements such as simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays. These innovations aim to provide more comprehensive, tissue-sparing, and clinically actionable molecular diagnostics for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis within a single workflow, enabling the detection of genomic variants like SNVs, indels, and copy-number alterations, alongside gene expression or fusion events. This approach contrasts with traditional NGS tests, which typically require separate assays or limited gene panels. For example, in November 2024, Caris Life Sciences, a US-based precision medicine company, obtained FDA approval for MI Cancer Seek, an NGS in vitro diagnostic that performs WES and WTS concurrently. This assay utilizes total nucleic acid (TNA) from FFPE tumor tissue to identify single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications in breast cancer. By consolidating DNA and RNA profiling into one test, it effectively preserves tissue, delivers clinically actionable companion diagnostic (CDx) indications across multiple tumor types, and accelerates therapy selection through a unified genomic blueprint.

Who Are The Prominent Players Across The Cancer In Vitro Diagnostics (IVD) Market?

Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics

Access The Complete Cancer In Vitro Diagnostics (IVD) Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

Which Region Is The Dominant Market In The Cancer In Vitro Diagnostics (IVD) Market?

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer In Vitro Diagnostics (IVD) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=27234&type=smp

Browse Through More Reports Similar to the Global Cancer In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Farm Equipment Rental Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/farm-equipment-rental-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Cancer In Vitro Diagnostics (IVD) Market In 2026 And 2030?

The cancer in vitro diagnostics (ivd) market has experienced robust expansion over recent years. Its valuation is projected to increase from $14.32 billion in 2025 to $15.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by factors such as the broadening of hospital diagnostic infrastructure, the rise in biomarker-based testing, the integration of PCR and immunoassay technologies, the increase in cancer screening initiatives, and advancements in laboratory automation.

The cancer in vitro diagnostics (IVD) market size is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach a valuation of $19.85 billion, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors driving this growth during the projected timeframe include the escalating demand for personalized oncology diagnostics, increased funding for genomic sequencing, the broadening scope of point-of-care cancer testing, the expanding adoption of cloud-based diagnostic platforms, and a heightened emphasis on precision medicine. Key trends anticipated during the forecast period encompass the wider embrace of molecular and genomic cancer testing, the growing application of companion diagnostics, the increasing incorporation of AI-driven data analysis, the broadening utility of liquid biopsy applications, and an intensified focus on identifying cancer at earlier stages.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

What Significant Factors Are Influencing The Cancer In Vitro Diagnostics (IVD) Market Expansion?

The growing occurrence of cancer is projected to fuel the expansion of the cancer in vitro diagnostics (IVD) market moving forward. Cancer is characterized by the uncontrolled proliferation and spread of abnormal cells within the body, which can invade adjacent tissues and form tumors. The escalating incidence of cancer stems from an aging populace, where increased life expectancy and reduced mortality from infectious diseases result in more elderly individuals facing a higher risk of developing cancer. Cancer in vitro diagnostics (IVD) contributes to cancer management by enabling early and precise detection, continuous monitoring, and effective treatment of the disease through laboratory tests conducted on patient samples, thereby facilitating timely therapeutic decisions and enhancing patient outcomes. For example, in January 2023, the American Cancer Society, a US-based professional organization dedicated to eradicating cancer, reported that 1,958,310 new cancer cases and 609,820 cancer deaths are expected in 2023 in the United States. Hence, the rising incidence of cancer is a primary catalyst for the growth of the cancer in vitro diagnostics (IVD) market.

Which Segment Classifications Are Used In The Cancer In Vitro Diagnostics (IVD) Market Segment Analysis?

The cancer in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Reagents And Kits, Instruments, Software And Services

2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Cytogenetics Or Liquid Biopsy Technologies, Molecular Diagnostics, Other Technology

3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer

4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Specialty Oncology Diagnostic Centers, Other End Users

Subsegments:

1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others

2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others

3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services

What Trends Are Affecting The Direction Of The Cancer In Vitro Diagnostics (IVD) Market?

Leading companies within the cancer in vitro diagnostics market are concentrating on innovations in cancer screening, such as blood-based colorectal cancer (CRC) screening, to deliver convenient, non-invasive, and accurate early detection of the disease. Blood-based CRC screening involves identifying cancer-associated molecular alterations, like circulating tumor DNA (ctDNA), within a patient’s blood sample to detect colorectal cancer in individuals at average risk. For instance, in July 2024, Guardant Health, Inc., a U.S.-based precision oncology company, secured U.S. Food and Drug Administration (FDA) approval for its Guardant Shield blood test as a primary colorectal cancer screening option. This test functions by analyzing a blood sample for specific ctDNA methylation patterns and other tumor-derived markers; its unique features include noninvasive collection, high analytical accuracy, and integration with clinical workflows for primary screening; its applications cover colorectal cancer early detection in average-risk adults; and its benefits encompass improved patient adherence, earlier detection of malignancy, a potential reduction in late-stage diagnoses, and eligibility for Medicare reimbursement, which enables broader population access to screening.

Which Firms Are Contributing To The Cancer In Vitro Diagnostics (IVD) Market Ecosystem?

Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics

Get The Full Cancer In Vitro Diagnostics (IVD) Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

Which Region Leads The Cancer In Vitro Diagnostics (IVD) Market In Terms Of Market Share?

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer In Vitro Diagnostics (IVD) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

Browse Through More Reports Similar to the Global Cancer In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

Hydraulic Pumps Market Report 2026

https://www.thebusinessresearchcompany.com/report/hydraulic-pumps-global-market-report

Hydraulics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hydraulics-global-market-report

Smart Elevators Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-elevators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Cancer In Vitro Diagnostics (IVD) Market Over The Period 2026–2030?

The cancer in vitro diagnostics (ivd) market has experienced significant expansion in recent years. This market is set to expand from $14.32 billion in 2025 to $15.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.0%. The growth observed in prior periods is attributable to factors such as the development of hospital diagnostic infrastructure, an increase in biomarker-based testing, the integration of PCR and immunoassay technologies, the proliferation of cancer screening programs, and advancements in laboratory automation.

The cancer in vitro diagnostics (ivd) market is expected to experience robust growth over the next few years. It is forecast to grow to $19.85 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. The expansion during the forecast period can be attributed to factors such as an increasing demand for personalized oncology diagnostics, rising investments in genomic sequencing, the broadening of point-of-care cancer testing, the growing integration of cloud-based diagnostic platforms, and a heightened focus on precision medicine. Key trends anticipated in this period include the increasing adoption of molecular and genomic cancer testing, a rising use of companion diagnostics, the growing integration of AI-driven data analysis, the expansion of liquid biopsy applications, and an enhanced focus on early cancer detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp

What Underlying Factors Are Accelerating The Growth Of The Cancer In Vitro Diagnostics (IVD) Market?

The increasing prevalence of cancer is anticipated to boost the expansion of the cancer in vitro diagnostics (IVD) market in the future. Cancer is characterized by the uncontrolled multiplication and dissemination of abnormal cells within the body, which can infiltrate adjacent tissues and develop into tumors. The heightened incidence of cancer is attributed to an aging demographic, where increased life expectancy and decreased mortality from infectious diseases result in a larger elderly population more susceptible to developing the disease. Cancer in vitro diagnostics (IVD) plays a crucial role in combating cancer by facilitating early and precise detection, ongoing monitoring, and effective management of the condition via laboratory analyses conducted on patient specimens, thereby enabling prompt treatment choices and enhancing patient prognoses. As an illustration, in January 2023, the American Cancer Society, a US-based professional organization dedicated to eliminating cancer, reported that 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. Consequently, the rising occurrence of cancer is a key factor propelling the growth of the cancer in vitro diagnostics (IVD) market.

How Is The Cancer In Vitro Diagnostics (IVD) Market Divided Into Its Major Segments?

The cancer in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Reagents And Kits, Instruments, Software And Services

2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Cytogenetics Or Liquid Biopsy Technologies, Molecular Diagnostics, Other Technology

3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer

4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Specialty Oncology Diagnostic Centers, Other End Users

Subsegments:

1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others

2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others

3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services

How Are Trends Transforming The Cancer In Vitro Diagnostics (IVD) Market Landscape?

Major companies operating in the cancer in vitro diagnostics market are prioritizing innovation in cancer screening, specifically through blood-based colorectal cancer (CRC) screening, to offer convenient, non-invasive, and accurate early detection of colorectal cancer. Blood-based CRC screening entails identifying cancer-associated molecular alterations, such as circulating tumor DNA (ctDNA), within a patient’s blood sample to detect colorectal cancer in average-risk individuals. For instance, in July 2024, Guardant Health, Inc., a U.S.-based precision oncology company, obtained U.S. Food and Drug Administration (FDA) approval for the Guardant Shield blood test as a primary option for colorectal cancer screening. The test functions by analyzing a blood sample for specific ctDNA methylation patterns and other tumor-derived markers; its distinct features include noninvasive collection, high analytical accuracy, and integration with clinical workflows for primary screening; its applications cover colorectal cancer early detection in average-risk adults; benefits encompass improved patient adherence, earlier detection of malignancy, potential reduction in late-stage diagnoses, and eligibility for Medicare reimbursement, thereby broadening population access to screening.

Who Are The Prominent Organizations Shaping The Cancer In Vitro Diagnostics (IVD) Market?

Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics

Read the full cancer in vitro diagnostics (ivd) market report here:

https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

Which Region Is Projected To Dominate The Cancer In Vitro Diagnostics (IVD) Market During The Forecast Period?

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer In Vitro Diagnostics (IVD) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27234&type=smp

Browse Through More Reports Similar to the Global Cancer In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

Commercial Fan And Air Purification Equipment Market

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Commercial Fan And Air Purification Equipment Market

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Farm Equipment Rental Global Market Report

https://www.thebusinessresearchcompany.com/report/farm-equipment-rental-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model